摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6-Chloro-3-[(Z)-(isonicotinoylhydrazono)(2,4,6-trioxohexahydro-5-pyrimidinyl)methyl]-4H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide

中文名称
——
中文别名
——
英文名称
6-Chloro-3-[(Z)-(isonicotinoylhydrazono)(2,4,6-trioxohexahydro-5-pyrimidinyl)methyl]-4H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide
英文别名
N-[(Z)-[(6-chloro-1,1-dioxo-7-sulfamoyl-4H-1λ6,2,4-benzothiadiazin-3-yl)-(2,4,6-trioxo-1,3-diazinan-5-yl)methylidene]amino]pyridine-4-carboxamide
6-Chloro-3-[(Z)-(isonicotinoylhydrazono)(2,4,6-trioxohexahydro-5-pyrimidinyl)methyl]-4H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide化学式
CAS
——
化学式
C18H13ClN8O8S2
mdl
——
分子量
568.9
InChiKey
CGIFIFRHVCDHOB-MXAYSNPKSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -0.9
  • 重原子数:
    37
  • 可旋转键数:
    5
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.06
  • 拓扑面积:
    265
  • 氢给体数:
    5
  • 氢受体数:
    12

文献信息

  • ISONIAZID MEDIATED HEALING OF WOUNDS AND ULCERS
    申请人:Buxbom Finn
    公开号:US20100184811A1
    公开(公告)日:2010-07-22
    The invention relates to the use of a compound(s) selected from isoniazid and isoniazid analogs of formula Ia, wherein R is —C(O)NHNH 2 , —C(O)NHNHC 1-6 alkyl, —C(O)NHN═C 1-6 alkenyl, —C(O)NHNHC 2-6 alkenyl, —C(O)NHC 1-6 alkyl, —C(O)NHC 2-6 alkenyl, —C(O)NHNHC(O)C 1-6 alkyl, —NHC(O)C 1-6 alkyl, —NHC(O)C 1-6 alkenyl, —NHC(O)NH 2 , —NHC(O)NHC 1-6 alkyl, —NHC(O)NHC 2-6 alkenyl, or —COOH, and wherein formula (Ia) optionally is further substituted with one or more substituents; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the preparation of a pharmaceutical composition for treating a condition selected from the group consisting of cutaneous lesions, wounds, ulcers and infarcts in a tissue area with compromised vascularisation, in an animal, such as a human subject. The compound is preferably isoniazid, or pharmaceutical acceptable salts, solvates or prodrugs thereof, and the conditions to be treated is for example selected from the group consisting of pressure ulcers, diabetic ulcers, arterial ulcers and anastomotic ulcers. The invention furthermore relates to a method of treating a condition selected from wounds, ulcers or infarcts in a tissue area with compromised vascularisation in an animal, such as a human subject.
查看更多